Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 in Advanced Malignant Solid Tumours
NCT06888830Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JS212 in solid tumor, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Dose-Limiting Toxicity up to 1 year, Adverse Events up to 2 years and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
JS212
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06888830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888830.